RU2012118668A - Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства - Google Patents
Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства Download PDFInfo
- Publication number
- RU2012118668A RU2012118668A RU2012118668/13A RU2012118668A RU2012118668A RU 2012118668 A RU2012118668 A RU 2012118668A RU 2012118668/13 A RU2012118668/13 A RU 2012118668/13A RU 2012118668 A RU2012118668 A RU 2012118668A RU 2012118668 A RU2012118668 A RU 2012118668A
- Authority
- RU
- Russia
- Prior art keywords
- agonist
- antimuscarinic agent
- antimuscarinic
- patient
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938609P | 2009-10-07 | 2009-10-07 | |
| US61/249,386 | 2009-10-07 | ||
| PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012118668A true RU2012118668A (ru) | 2013-11-20 |
Family
ID=43857059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012118668/13A RU2012118668A (ru) | 2009-10-07 | 2010-09-27 | Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120202819A1 (OSRAM) |
| EP (1) | EP2485595A4 (OSRAM) |
| JP (1) | JP5738871B2 (OSRAM) |
| KR (1) | KR20120093859A (OSRAM) |
| CN (1) | CN102638987A (OSRAM) |
| AU (1) | AU2010303811B2 (OSRAM) |
| BR (1) | BR112012007829A2 (OSRAM) |
| CA (1) | CA2774992A1 (OSRAM) |
| IL (1) | IL218756A0 (OSRAM) |
| IN (1) | IN2012DN02782A (OSRAM) |
| MX (1) | MX2012004134A (OSRAM) |
| NZ (1) | NZ599233A (OSRAM) |
| RU (1) | RU2012118668A (OSRAM) |
| WO (1) | WO2011043942A1 (OSRAM) |
| ZA (1) | ZA201202520B (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642661B2 (en) * | 2010-08-03 | 2014-02-04 | Altherx, Inc. | Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| EP3167885A1 (en) * | 2011-05-10 | 2017-05-17 | TheraVida, Inc. | Combinations of solifenacin and pilocarpine for the treatment of overactive bladder |
| US9809536B2 (en) | 2011-10-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| JP6063948B2 (ja) * | 2011-10-27 | 2017-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ベータ３アゴニストおよび中間体を製造するプロセス |
| SG11201404776PA (en) * | 2012-02-09 | 2014-09-26 | Altherx Inc | Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
| SMT201900508T1 (it) * | 2013-03-15 | 2019-11-13 | Merck Sharp & Dohme | Processo per preparare beta 3 agonisti e intermedi |
| ES2910361T3 (es) * | 2013-07-23 | 2022-05-12 | Serenity Pharmaceuticals Llc | Composiciones que comprenden desmopresina en combinación con un agonista del receptor adrenérgico beta-3 |
| CN106999538A (zh) | 2014-11-20 | 2017-08-01 | 阿勒根公司 | 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物 |
| KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| KR20250099259A (ko) | 2017-06-06 | 2025-07-01 | 유로반트 사이언시즈 게엠베하 | 과민성 방광의 치료를 위한 비베그론의 용도 |
| CN110869053A (zh) * | 2017-06-06 | 2020-03-06 | 乌洛万特科学有限公司 | 给药维贝隆以治疗膀胱过度活动症 |
| CN118078835A (zh) * | 2017-12-21 | 2024-05-28 | 杏林制药株式会社 | 用于夜间尿频的治疗剂 |
| WO2020115705A1 (en) | 2018-12-05 | 2020-06-11 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TWI295669B (en) * | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| JP2008516909A (ja) * | 2004-10-18 | 2008-05-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用 |
| JP2010522751A (ja) * | 2007-03-29 | 2010-07-08 | メルク・シャープ・エンド・ドーム・コーポレイション | 下部尿路症状の治療のための併用療法 |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Withdrawn
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en not_active Ceased
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011043942A1 (en) | 2011-04-14 |
| ZA201202520B (en) | 2012-12-27 |
| US20120202819A1 (en) | 2012-08-09 |
| JP2013507363A (ja) | 2013-03-04 |
| AU2010303811A1 (en) | 2012-04-19 |
| MX2012004134A (es) | 2012-05-08 |
| CN102638987A (zh) | 2012-08-15 |
| AU2010303811B2 (en) | 2013-01-24 |
| KR20120093859A (ko) | 2012-08-23 |
| NZ599233A (en) | 2013-04-26 |
| IL218756A0 (en) | 2012-06-28 |
| BR112012007829A2 (pt) | 2015-09-22 |
| JP5738871B2 (ja) | 2015-06-24 |
| EP2485595A1 (en) | 2012-08-15 |
| EP2485595A4 (en) | 2014-03-12 |
| IN2012DN02782A (OSRAM) | 2015-09-18 |
| CA2774992A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012118668A (ru) | Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства | |
| JP4993523B2 (ja) | ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用 | |
| US8642661B2 (en) | Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists | |
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| US20170035716A1 (en) | Method of using solabegron | |
| US20090312242A1 (en) | Flibanserin for the treatment of urinary incontinence and related diseases | |
| JP2006509751A5 (OSRAM) | ||
| RU2016141314A (ru) | Составы разагилина с пролонгированным высвобождением и их применение | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| JP2012533595A5 (OSRAM) | ||
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| JP6433785B2 (ja) | トランス−クロミフェン代謝物およびその使用 | |
| JP2017530163A5 (OSRAM) | ||
| JP2019089796A5 (OSRAM) | ||
| TW201513850A (zh) | 用於治療癌症之氧烯洛爾（ｏｘｐｒｅｎｏｌｏｌ）組合物 | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| Georgescu et al. | The role of alpha-1blockers in the medical expulsive therapy for ureteral calculi-a prospective controlled randomized study comparing tamusolin and silodosin | |
| Goldberg | Antidepressant use in the elderly: current status of nefazodone, venlafaxine and moclobemide | |
| CN104684549A (zh) | 治疗膀胱过度活动症的毒蕈碱性受体拮抗剂和β-3肾上腺素能受体激动剂的组合 | |
| RU2010144795A (ru) | Применение комбинации уденафила и алфузозина или оксибутинина для лечения гиперактивного мочевого пузыря | |
| UY28457A1 (es) | Nueva composición | |
| JP2008531696A5 (OSRAM) | ||
| RU2013149635A (ru) | Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря | |
| JP2013541582A5 (OSRAM) | ||
| CN102716120B (zh) | (3r)-去-o-甲基毛狄泼老素在制备预防或治疗抑郁症的药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150618 |